A5100695149- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Adrenal and Paraganglionic Tumors
- Microtubule and mitosis dynamics
- Radiomics and Machine Learning in Medical Imaging
- Neurofibromatosis and Schwannoma Cases
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Endometrial and Cervical Cancer Treatments
- Breast Cancer Treatment Studies
- Breast Implant and Reconstruction
- Sarcoma Diagnosis and Treatment
Xijing Hospital
2023
Sidney Kimmel Comprehensive Cancer Center
2023
Johns Hopkins University
2023
Air Force Medical University
2023
Abstract Purpose: Isocitrate dehydrogenase (IDH)-mutant gliomas are usually treated with radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae during patients’ most productive years. We report our experience using off-label first-in-class mutant IDH1 inhibitor ivosidenib its impact on tumor volume in IDH-mutant gliomas. Experimental Design: retrospectively analyzed patients ages ≥18 years radiation/chemotherapy-naïve, IDH1, nonenhancing, radiographically active,...
<div>Abstract<p>Purpose: Isocitrate dehydrogenase (IDH) mutant gliomas are usually treated with radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae during patients’ most productive years. We report our experience using off-label first-inclass IDH1mut-inhibitor ivosidenib its impact on tumor volume in IDHmut gliomas. Experimental Design: retrospectively analyzed patients aged ≥18 years radiation/chemotherapy-naïve, IDH1mut, non-enhancing,...
<div>Abstract<p>Purpose: Isocitrate dehydrogenase (IDH) mutant gliomas are usually treated with radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae during patients’ most productive years. We report our experience using off-label first-inclass IDH1mut-inhibitor ivosidenib its impact on tumor volume in IDHmut gliomas. Experimental Design: retrospectively analyzed patients aged ≥18 years radiation/chemotherapy-naïve, IDH1mut, non-enhancing,...
<div>AbstractPurpose:<p>Isocitrate dehydrogenase (IDH)-mutant gliomas are usually treated with radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae during patients’ most productive years. We report our experience using off-label first-in-class mutant IDH1 inhibitor ivosidenib its impact on tumor volume in IDH-mutant gliomas.</p>Experimental Design:<p>We retrospectively analyzed patients ages ≥18 years radiation/chemotherapy-naïve, IDH1,...
<div>AbstractPurpose:<p>Isocitrate dehydrogenase (IDH)-mutant gliomas are usually treated with radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae during patients’ most productive years. We report our experience using off-label first-in-class mutant IDH1 inhibitor ivosidenib its impact on tumor volume in IDH-mutant gliomas.</p>Experimental Design:<p>We retrospectively analyzed patients ages ≥18 years radiation/chemotherapy-naïve, IDH1,...